Share on StockTwits

GlaxoSmithKline plc (LON:GSK)‘s stock had its “underperform” rating reiterated by research analysts at Credit Suisse in a report released on Friday. They currently have a GBX 1,475 ($24.74) price target on the stock. Credit Suisse’s price objective suggests a potential upside of 5.73% from the stock’s previous close.

Several other analysts have also recently commented on the stock. Analysts at Jefferies Group reiterated a “hold” rating on shares of GlaxoSmithKline plc in a research note on Monday. They now have a GBX 1,385 ($23.23) price target on the stock. Separately, analysts at Beaufort Securities reiterated a “buy” rating on shares of GlaxoSmithKline plc in a research note on Monday, August 4th. Finally, analysts at Shore Capital reiterated a “buy” rating on shares of GlaxoSmithKline plc in a research note on Monday, August 4th. Four research analysts have rated the stock with a sell rating, twelve have issued a hold rating and six have assigned a buy rating to the stock. GlaxoSmithKline plc has a consensus rating of “Hold” and a consensus price target of GBX 1,634.81 ($27.43).

Shares of GlaxoSmithKline plc (LON:GSK) opened at 1408.00 on Friday. GlaxoSmithKline plc has a 1-year low of GBX 1200.668 and a 1-year high of GBX 1706.00. The stock’s 50-day moving average is GBX 1495. and its 200-day moving average is GBX 1587.06. The company’s market cap is £67.640 billion.

The company also recently declared a dividend, which is scheduled for Thursday, October 2nd. Investors of record on Wednesday, August 6th will be given a dividend of GBX 19 ($0.32) per share. This represents a yield of 1.28%. The ex-dividend date of this dividend is Wednesday, August 6th.

GlaxoSmithKline plc (LON:GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with Analyst Ratings Network's FREE daily email newsletter.